{
    "clinical_study": {
        "@rank": "156443", 
        "arm_group": {
            "arm_group_label": "Irvine Gass Syndrome", 
            "description": "Patients older than 18 years who develop macula edema secondary to cataract surgery.\nGroup may receive intravitreal Ozurdex medication in case of persistent macular edema."
        }, 
        "brief_summary": {
            "textblock": "To analyze macula edema formation after cataract surgery called Irvine-Gass-Syndrome."
        }, 
        "brief_title": "Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Macular Edema", 
            "Visual Acuity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "20 to 25 patients suffering from Irvine Gass Syndrom should be monitored for at least six\n      months, controlled monthly. In all cases best corrected visual acuity, Spectralis-OCT\n      (volume thickness scan), fundus photography (Optomap), intraocular pressure, slitlamp\n      assessment and indirect ophthalmoscopy should be performed on every visit. Fluorescein\n      angiography should be performed at baseline and after 3 and 6 months.\n\n      Inclusion criteria:\n\n      Patients older than 18 years who develop macula edema secondary to cataract surgery.\n\n      - Consent agreement - Patients should be informed that it is possible to get an active\n      medication (Ozurdex implant) as an \"on label\" indication from the health insurance company\n      if the diagnosis is accepted as an intraocular inflammation form of \"Uveitis posterior\".\n\n      Exclusion criteria:\n\n      Visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular\n      disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use of\n      systemic, periocular, or intraocular corticosteroids within 30 days.\n\n      Outcome:\n\n        -  BCVA\n\n        -  Patients suffering from diabetes mellitus should be evaluated also separately.\n\n        -  Change in central retinal thickness using optical coherence tomography (OCT)\n\n        -  Secondary parameters (elevated IOP, retinal detachments, vitreous hemorrhage,\n           endophthalmitis rates)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients older than 18 years who develop macula edema secondary to cataract surgery\n\n        Exclusion Criteria:\n\n        Visual acuity worse than 20/400, known history of glaucoma and steroid response, any\n        macular disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy,\n        use of systemic, periocular, or intraocular corticosteroids within 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients older than 18 years."
            }
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945892", 
            "org_study_id": "MAF/ISS/OPH/RET/011"
        }, 
        "intervention": {
            "arm_group_label": "Irvine Gass Syndrome", 
            "description": "- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an \"on label\" indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of \"Uveitis posterior\".", 
            "intervention_name": "Ozurdex", 
            "intervention_type": "Drug", 
            "other_name": "Dexamethasone-implant"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "macular edema, irvine gass syndrome, ozurdex", 
        "lastchanged_date": "September 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Munich", 
                    "country": "Germany", 
                    "zip": "80336"
                }, 
                "name": "Dept. of Ophthalmology, LMU Munich"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Ozurdex as an Treatment Option for Macula Edema Due to Irvine Gass Syndrome", 
        "overall_official": [
            {
                "affiliation": "LMU Munich", 
                "last_name": "Wolfgang J Mayer, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "LMU Munich", 
                "last_name": "Christos Haritoglou, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Best corrected visual acuity and visual acuity gain after 6 and 12 months.", 
            "measure": "Visual acuity", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945892"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ludwig-Maximilians - University of Munich", 
            "investigator_full_name": "Wolfgang Mayer", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Retinal thickness measured by OCT.", 
                "measure": "Retinal Thickness", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Intraocular pressure using Goldmann applanation tonometer", 
                "measure": "Intraocular pressure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Ludwig-Maximilians - University of Munich", 
        "sponsors": {
            "collaborator": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ludwig-Maximilians - University of Munich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}